Docking And Molecular Modelling Of Benzothiazole Derivatives As Antidiabetic Activity

Abstract

Diabetes mellitus is a metabolic alteration characterized by hyperglycemia resulting from defects in insulin secretion, action, or both, currently affecting 3% of the world population. This complex metabolic syndrome is a major human health concern in the world and is estimated to affect 300 million people by the year 2025. Taha et al., recently worked on, a novel of benzothiazole hybrid having benzohydrazide moiety was synthesis and evaluated for their α-glucosidase inhibitory activities. Out of the synthesised compound N'-(4-chlorobenzylidene)-4-(benzo[d]thiazol-2-yl) benzohydrazide was found to be the most active compound when compared with standard acarbose. Quest for novel, more potent then tradition medicines, safer and stable α-glucosidase inhibitors is necessity for today’s world and thrust patients for the treatment of DM. The objective of current study is to design, synthesize some new benzothiazole derivatives and evaluate it for α-glucosidase inhibitory activity, having more potency and fewer side effects.